ReviewPharmacoEconomics2013
Vemurafenib for the treatment of locally advanced or metastatic BRAF V600 mutation-positive malignant melanoma: a NICE single technology appraisal.
Sophie Beale et al.PubMed ↗Publisher ↗
No numbers read from the abstract.
12 papers cite it
this paperpooled itcites it